Researchers at Columbia University College of Dental Medicine have developed an exosome-based platform, "safeEXO-Cas," that significantly enhances the delivery of CRISPR/Cas9 genome editing components ...
CAMBRIDGE, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)--Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to address the longtime challenge of bringing their treatments to patients by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results